Research programme: antifungals - Schering-Plough

Drug Profile

Research programme: antifungals - Schering-Plough

Alternative Names: SCH-725680

Latest Information Update: 17 Nov 2009

Price : $50

At a glance

  • Originator Oscient Pharmaceuticals; Schering-Plough
  • Developer Schering-Plough
  • Class Benzopyrans
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Mycoses

Most Recent Events

  • 18 Jun 2007 Preclinical development is ongoing
  • 17 May 2006 This programme is still in active development
  • 13 Apr 2004 Genome Therapeutics is now called Oscient Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top